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2Abstract 
GalNAc-glycopeptides derived from mucin MUC1 are an important class of tumor-
associated antigens. -O-glycosylation forces the peptide to adopt an extended 
conformation in solution, which is far from the structure observed in complexes with a 
model anti-MUC1 antibody. Herein, we propose a new strategy to design potent antigen 
mimics based on modulating peptide/carbohydrate interactions by means of O→S/Se 
replacement at the glycosidic linkage. These minimal chemical modifications bring about 
two key structural changes to the glycopeptide. They increase the carbohydrate-peptide 
distance and change the orientation and dynamics of the glycosidic linkage. As a result, 
the peptide acquires a preorganized and optimal structure suited for antibody binding. 
Accordingly, these new glycopeptides display improved binding towards a representative 
anti-MUC1 antibody relative to the native antigens. To prove the potential of these 
glycopeptides as tumor-associated MUC1 antigen mimics, the derivative bearing the S-
glycosidic linkage was conjugated to gold nanoparticles and tested as an immunogenic 
formulation in mice without any adjuvant, that resulted in a significant humoral immune 
response. Importantly, the mice antisera recognize cancer cells in biopsies of breast-
cancer patients with high selectivity. This finding demonstrates that the antibodies 
elicited against the mimetic antigen indeed recognize the naturally occurring antigen in 
its physiological context. Clinically, the exploitation of tumor-associated antigen mimics 
may contribute to the development of cancer vaccines and to the improvement of cancer 
diagnosis based on anti-MUC1 antibodies. The methodology presented here is of 
general interest for applications because it may be extended to modulate the affinity of 
biologically relevant glycopeptides towards their receptors.
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3Introduction
MUC1 mucin is an O-glycoprotein overexpressed in many tumor tissues.1-4 Although in 
healthy cells the backbone of this protein is decorated with complex glycans, in cancer 
cells this backbone carries rather simple and truncated oligosaccharides. Consequently, 
different tumor-associated carbohydrate antigens, such as the Tn determinant (-O-
GalNAc-Ser/Thr),5 are presented to the immune system and can be identified by anti-
MUC1 antibodies. The peptide fragment Ala-Pro-Asp-Thr-Arg-Pro, which includes the 
immunodominant PDTRP region of MUC1 tandem repeats,6 constitutes the minimum 
epitope recognized by these antibodies.7 Partially glycosylated MUC1 derivatives have 
been used to prepare immunogenic formulations towards the development of therapeutic 
cancer vaccines.8-12 Similarly, unnatural glycopeptides that mimic tumor-associated 
MUC1 can find application as biosensors for the detection of cancerous cells.13 An 
intriguing observation about the structural characteristics of these peptides is that -O-
glycosylation with GalNAc forces the underlying peptide into an extended conformation 
in solution as a result of stabilizing interactions, which include  direct14 or water-mediated 
hydrogen bonds, between the peptide and the carbohydrate moiety (Figure 1A).15-17 In 
contrast, the X-ray structure of the glycopeptide epitope bound to an anti-MUC1 antibody 
(SM3) 18 revealed a folded conformation around the glycosylated Thr (Figure 1A).19 In 
this case, the sugar shifts the structure of the peptide in solution away from that adopted 
upon antibody binding. This conformational entropic penalty is however compensated 
for by favorable enthalpic contributions (hydrogen bonds and CH/ stabilizing 
interactions)20,21  between the sugar moiety and the antibody. As a result, a modest net 
increase in binding affinity (around 3-fold) is observed for the glycosylated versus the 
non-glycosylated peptide.
Herein, we propose a rational approach based on single-atom substitution (O→S/Se) at 
the glycosidic linkage to obtain potent antigens with an improved affinity towards anti-
MUC1 antibodies (Figure 1B). This simple modification increases  the distance between 
the sugar and the peptide fragment — sulfur (or selenium) is larger than oxygen — which 
in turn minimizes the exo-anomeric effect22 and alters the flexibility and the most stable 
conformation of the glycosidic linkage towards the one optimized for the antibody. 
Overall, these glycopeptides adopt a distinct structure in solution, which differs markedly 
from their oxygenated counterparts, thus avoiding the subsequent entropic cost 
associated to the extended-to-folded conformational transition of the O-glycopeptide in 
the bound state. In this work, we describe the strong binding of these glycopeptides to a 
model MUC1 antibody and demonstrate the possibility of using them as tumor-
associated MUC1 mimics when they are incorporated in immunogenic formulations. In 
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4fact, the antibodies elicited in mice recognize selectively the natural occurring tumor-
associated MUC1 epitopes displayed on cancer cells in biopsies of breast-cancer 
patients.
Figure 1. (A) Major conformation of a tumor-associated MUC1 glycopeptide in solution 
(top) and bound to the SM3 antibody (bottom). (B) Proposed strategy to allow the peptide 
backbone to adopt a preorganized structure in solution. 
Results and Discussion
Synthesis and conformational analysis of the unnatural glycopeptides in solution
Glycopeptides 2* and 3* (Figure 2A) were designed to feature S-(-D-GalNAc)-
thiothreonine (SThr*) or Se-(-D-GalNAc)-selenothreonine (SeThr*), respectively, as 
the fourth residue of the Ala-Pro-Asp-Xaa-Arg-Pro epitope. Naturally occurring 
glycopeptide 1*, which has a threonine residue at this position, and non-glycosylated 
variants 1 and 2 were prepared for comparison.
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5Figure 2. (A) Glycopeptides synthesized and studied in this work, comprising the 
minimum epitope recognized by most anti-MUC1 antibodies.7 (B) Sections of the 500 ms 
2D-ROESY spectrum (400 MHz) in H2O/D2O (9:1) at 298 K and pH = 6.5 of glycopeptides 
1* (upper panel) and 2* (lower panel) that show the amide region. Diagonal peaks are in 
red. ROE contacts are represented as blue cross-peaks. A second set of signals is 
observed corresponding to the cis configuration of the amide bond of proline residues. 
23 (C) Geometry and flexibility at the glycosidic linkage and peptide backbone for the 
unnatural SThr residue of glycopeptide 2* in solution derived from 20 ns experiment-
guided MD simulations. The yellow circles correspond to the conformation found in the 
crystal structure of glycopeptide 1* bound to a single-chain variable fragment of the SM3 
antibody (scFv-SM3, PDB ID: 5A2K). (D) Structural ensembles derived from 20 ns 
experiment-guided MD simulations for compounds 1*, 2* and 3* in solution, together with 
the conformation of the peptide backbone of 1* (in blue) found by X-ray crystallography 
bound to scFv-SM3 antibody (PDB ID: 5A2K). (E) Circular dichroism (CD) spectra of 
compounds 1* and 2* (0.25 mM in sodium phosphate buffer, pH = 7.5, 20 oC). 
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6Although the synthesis of the amino acid thiothreonine (SThr) has been previously 
described,24-26 the preparation of conveniently protected thiothreonine and 
selenothreonine derivatives, as well as glycopeptides 2* and 3*, has not been reported 
yet. As an example, the synthesis of building block 4, which is ready to be used in solid 
phase peptide synthesis (SPPS), is shown in Scheme 1. Conveniently protected 
threonine 5 was reacted with triphenylphosphine and iodine with imidazole as a base to 
afford the iodo-derivative 6 with total inversion of configuration at the -carbon.27 In 
parallel, selenosugar 9 was prepared in two steps from peracetylated compound 7. In 
the first step, 7 was treated with Woollin’s reagent and pyridine to give selenazoline 8 in 
70% yield. Hydrolysis of 8 with trifluoroacetic acid (TFA) in water afforded selenosugar 
9 in moderate yield and as a dimer because of the formation of a diselenide bond. The 
key step in the synthesis of building block 4 is the nucleophilic attack of 9, previously 
reduced in situ with sodium borohydride, at iodo-derivative 6. This reaction proceeded in 
51% yield and with total inversion of the configuration at the -carbon of the 
selenothreonine surrogate and completely preserved the -configuration at the anomeric 
carbon as determined by 1H NMR spectroscopy (see Synthesis section in Supporting 
Information). Subsequent deprotection steps gave the desired compound 4 in 42% 
overall yield from 9. A similar strategy was used to prepare the building block of SThr * 
(see Synthesis section in Supporting Information).
TFA, H2O
CH2Cl2
3.5 h, 0 °Crt O
HN
AcO
AcO OAc
O
Se
2
31%
O
OAc
NHAc
AcO
AcO OAc Woollin's reagentPyridine, toluene
reflux, 14 h OAcO
AcO OAc
N Se70%
8 97
O
AcHN
AcO
AcO OAc
Se
1) NaBH4 ( 3 equiv)
0°C rt, 2 h
2) 6 (1 equiv)
0°C rt,3 h
10
Me
BocHN
O
O
9
1) TFA/CH2Cl2
25 ºC, 2.5 h
2) FmocCl
DIEA, CH2Cl2, rt, 1.5 h
Pd(PPh3)4, morpholine
THF, 25 ºC, 30 min
O
OAcAcO
AcO
AcHN
Se
FmocHN CO2R'
Me
11, R=Allyl, 72%
4, R=H, 58%
I
BocHN CO2Allyl
6
HO
BocHN CO2Allyl
PPh3, I2
Imidazole
25 ºC, 1.5 h
N-Boc-L-threonine
allyl ester (5)
80%
51%
Scheme 1. Synthetic route followed for the preparation of building block 4. Boc =tert-
butyloxycarbonyl. DIEA=N,N-diisopropylethylamine. Fmoc=fluorenylmethoxycarbonyl.
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7All (glyco)peptides were synthesized with microwave-assisted SPPS (MW-SPPS) by 
following our reported protocol13 (Supporting Information). Next, we performed a 
thorough conformational analysis of the unnatural glycopeptides 2* and 3* in solution, by 
combining NMR spectroscopic measurements with molecular dynamics (MD) 
simulations (Figures 2B, 2C and 2D; see also Figures S1 and S2). The lack of a ROESY 
cross-peak between the NH of the unnatural SThr4 residue (or SeThr4) and the NH of 
GalNAc (Figure 2B, left panel), characteristic of the eclipsed conformation of the 
glycosidic linkage in GalNAc-Thr,16,17 together with the presence of a cross-peak 
between the NH of SThr4 (or SeThr4)  and H1 of GalNAc (Figure 2B, right panel), 
suggest a different conformation for the S- and Se-containing glycosidic linkages in 2* 
and 3*, respectively, with regard to GalNAc-Thr (Figure 2B). Clear structural differences 
between glycopeptides 1* and the two surrogates 2* and 3* are also observable in their 
peptide backbone. In particular, the sequential NH-NH ROESY cross-peak that connects 
residues 4 and 5 in compounds 2* and 3* hints to a folded conformation of the 
glycosylated SThr and SeThr residues (Figure 2B, left panel).28 The relevant proton-
proton distances for the conformational analysis derived from the ROESY spectrum of 
each compound were then used as time-averaged restraints29,30 in experiment-guided 
MD simulations in accordance with our well-established protocol.31,32 The good 
agreement between the experimental and theoretical derived distances validates our 
calculations (Table S1 and Figures S4 and S5). According to the MD simulations, the S- 
and Se-glycosidic linkages of 2* and 3* display a unique conformation centered at / ≈ 
65º/70º, which agrees with the exo-anomeric effect22 and deviates for the more eclipsed 
arrangement observed for 1* (/ ≈ 65º/120º) 16 (Figure 2C and Figure S6). It is important 
to note that this conformer lies at one of the local minima calculated for methyl 4-thio-α-
maltoside33 and it is similar to that explored by an unnatural Tn antigen with a cysteine 
residue previously prepared in our lab.34 The side chain of the unnatural residues in 2* 
and 3* is rather rigid in solution, with conformers characterized by 1 = 60º. The slightly 
different geometry and flexibility of S- and Se-glycosidic linkages relative to the O-
glycosidic linkage, together with the larger size of the S and Se atoms, precludes an 
effective interaction between the peptide backbone and the carbohydrate. In fact, neither 
significant hydrogen bonds nor water pockets were observed between these moieties. 
This finding emphasizes the synergistic roles of the methyl group of the threonine and 
the glycosidic oxygen atom in defining the conformational preference of the natural Tn-
Thr antigen.
Regarding the peptide backbone, compounds 2* and 3* showed conformations 
characterized by a folded structure around the unnatural residues SThr4 or SeThr4, 
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8respectively (Figures 2, S4 and S5). This arrangement of the peptide differs from that 
previously reported for 1* (Figure 2D), which displays mostly a -like extended 
conformation in solution (Figure 2D) owing to water-mediated hydrogen bonds between 
the peptide and GalNAc.17,32 The different arrangement of the backbone was also 
supported by the CD spectra (Figure 2E). Furthermore, according to unrestrained 1 s 
MD simulations in explicit water, non-glycosylated peptide 2 exhibits a random coil 
conformation in solution (Figure S3), which is different from the structure adopted by 2*. 
Thus, despite the larger distance between the carbohydrate and the peptide backbone 
in glycopeptides 2* and 3*, our results suggest that the sugar moiety still plays a role as 
a structural modulator, which presumably may reduce the conformational space 
accessible to the peptide backbone. Overall, unnatural glycopeptides 2* and 3* display 
markedly different conformations in solution relative to the naturally occurring 
counterpart 1* that are induced by the replacement of a single-atom in these compounds 
(O→S/Se). In particular, the conformational preference both at the glycosidic linkage and 
the unnatural residue (SThr4 or SeThr4) are shifted towards those of 1* bound to an anti-
MUC1 monoclonal antibody.19 Thus, the energy cost associated to a conformational 
change of the glycopeptide from extended in solution to folded in the bound state is 
expected to be minimized (vide infra). 
Conformational analysis of the unnatural glycopeptides 2* and 3* bound to scFv-SM3 
Crystals suitable for X-ray diffraction analysis of a recombinantly expressed single-chain 
variable fragment of the SM3 antibody (scFv-SM3) complexed with 2* and 3* were 
obtained. The X-ray structure of these complexes, solved at high resolution (< 2.0 Å, 
Table S2 and Figure 3, and Figure S7, PDB IDs: 5N7B and 6FRJ) revealed that the 
conformation of the bound peptide was nearly identical to that adopted by 1* when bound 
to scFv-SM3 (Figure 3C). This result demonstrates that the antibody recognizes a well-
defined epitope conformation, regardless of the nature of the glycosylated amino acid, 
characterized by torsion angles at the glycosylated residue typical of folded structures ( 
and  close to 88º and 10º, respectively). As detailed above, this conformation is also 
adopted in solution by the peptide backbone of glycopeptides 2* and 3* (Figure 2D and 
Figures S4 and S5). As for glycopeptide 1*, the stabilizing contacts in complexes 
2*/scFv-SM3 and 3*/scFv-SM3 involve several hydrogen bonds, some of which are 
mediated by water molecules, as well as several stacking interactions (Figures 3A and 
3B). 
Of note, two distinct binding modes are observed for glycopeptide 2* in complex with 
scFv-SM3 that differ solely in the geometry of the glycosidic linkage. Binding mode A is 
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9characterized by a glycosidic linkage with / = 87º/74º. This conformer corresponds to 
the structure adopted by 2* in solution (Figures 2C and 3A). Alternatively, in binding 
mode B, with glycosidic linkage angles / ≈ 90º/90º, the glycopeptide structure is 
stabilized by an intramolecular hydrogen bond between the NH of SThr4 and the 
endocyclic oxygen (O5) of GalNAc (Figure 3A). This binding mode was also found for 
the serine and a cysteine variants of the immunodominant PDTRP region of MUC1.19 
Although binding mode A allows the N-acetyl group of GalNAc to stack with the aromatic 
ring of a tryptophan residue (Trp33H) of scFv-SM3, mode B impedes any direct contact 
between the sugar and the antibody. The electron density observed for the GalNAc 
moiety of glycopeptide 3* is rather weak, which may suggest the simultaneous presence 
of both binding modes observed for derivative 2* (Figure 3B and Figure S7). Extensive 
MD simulations performed on the 2*/scFv-SM3 complex supported that both binding 
modes (A and B) are stable in solution (Figures S8 and S9).
Interestingly, quantum mechanical (QM) calculations performed on abbreviated models 
of glycopeptides 1* and 2* (compounds 1’ and 2’, respectively; see Tables S3 and S4 
and Figure S10) indicate that the larger repulsion between the -methyl group of Thr and 
H1 of GalNAc in glycopeptide 1* as a result of the smaller size of the oxygen atom 
together with the more distorted geometry of the intramolecular hydrogen bond O5 
(GalNAc) and NH (Thr), leads to the lack of binding mode B in the natural occurring 
glycopeptide. 
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10
Figure 3. X-ray structures of glycopeptides 2* (A) and 3* (B) bound to the scFv-SM3 
antibody (PDB IDs: 5N7B and 6FRJ). Glycopeptides carbon atoms are shown in green. 
Carbon atoms of key residues of scFv-SM3 are colored yellow. Green dashed lines 
indicate hydrogen bonds between peptide backbones and scFv-SM3 antibody. Pink 
dashed lines indicate the hydrogen bond between the NH of SThr (or SeThr) and O5 
(see dashed boxes). Blue dashed line indicates a CH/ interaction between the N-acetyl 
group of GalNAc and Trp33H in binding mode A. Note that the density corresponding to 
the GalNAc moiety in glycopeptide 3* is only partial (Figure S7), strongly suggesting the 
existence of local flexibility. (C) Superposition of glycopeptides 1*, 2* and 3* in complex 
to the scFv-SM3 antibody, which shows that the antibody recognizes the same 
conformation for the peptide backbone, regardless of the nature of the glycosylated 
residue. 
Affinity of the unnatural glycopeptides 2* and 3* towards scFv-SM3 
Detailed conformational analysis of glycopeptides 2* and 3* both in solution and bound 
to scFv-SM3 in comparison to that assumed in solution indicates that the structure of 
these peptides is preorganized for binding, which this is not the case for 1*. Accordingly, 
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11
a tighter binding would be expected for the unnatural derivatives (vide supra). To confirm 
this hypothesis, their binding affinities (KD) to scFv-SM3 were measured by using surface 
plasmon resonance (SPR) assays (Figure 4 and Figures S11-S15). The highest affinities 
were observed for the unnatural glycopeptides 2* and 3* (with KD = 168 and 193 M at 
25 ºC, respectively). Notably, an improved affinity (20-fold) was obtained relative to 
unglycosylated epitope 1. The variation in the affinity of natural glycopeptide 1* with 
temperature is higher than for the unnatural counterparts. This result may indicate the 
existence of an extra entropic penalty associated with the binding of 1* (Figure 4B) and 
highlights in this respect the inherently different conformational behavior of unnatural 
glycopeptides 2* and 3*, as already concluded through NMR experiments and MD 
simulations.
Figure 4. (A) SPR curves and response-concentration fit obtained for the binding of 2* 
towards scFv-SM3. (B) KD constants derived from SPR experiments for the studied 
(glyco)peptides.
Preparation and in vivo studies of an anticancer vaccine based on an engineered 
glycopeptide. 
As discussed above, partially glycosylated peptides with sequences derived from MUC1 
are an exciting niche of research for the development of therapeutic anticancer vaccines. 
As yet, none of them have so far succeeded in clinical trials, underlining the difficulty of 
inducing effective and durable immunological responses to a self-antigen such as tumor-
associated-MUC1.12 Additional research is needed to understand how to break tolerance 
to self-antigens, which includes knowledge on how vaccine formulation are processed 
by the immune system and (glyco)peptide antigens are presented by the major 
histocompatibility complex (MHC) I and II. 35-38
The results presented in this work prove that a single atom substitution at the glycosidic 
linkage has a remarkable impact on the structure of the glycopeptide in solution, 
especially at the glycosylated residue, which in turn may significantly affect peptide 
presentation and overall vaccine efficacy. Additionally, natural glycopeptides may suffer 
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degradation from endogenous glycosidases,39,40 which in turn alters their effectiveness 
as immunizing antigens,41 while S-glycoside analogs have improved stability.42,43 These 
two considerations prompted us to test whether structurally engineered glycopeptide 12 
could be used as tumor-associated antigen mimic through a nanoparticle-based 
immunogenic formulation (Figure 5A). Glycopeptide 12 comprises the complete tandem 
repeat sequence of MUC1 and features the SThr* residue described above. Additionally, 
this glycopeptide displays a (4S)-4-fluoro-L-proline (fPro) residue that replaces the Pro 
moiety at the beginning of the PDTRP epitope sequence. The motivation to select this 
doubly engineered glycopeptide was to combine the entropic benefit induced by SThr* 
by preorganizing the epitope structure for optimal binding, and the beneficial enthalpic 
effect produced by the fPro by enhancing antigen-antibody interactions.13 Moreover, one 
of us has been previously shown that PEGylated AuNPs could be used as efficient 
antigen carriers to establish humoral immunity against the tumor-associated form of 
MUC1 in mice, and the elicited antibodies did recognize the natural antigen on human 
breast cancer cells.44 These promising results led us to conjugate the MUC1 antigen 
mimic glycopeptide 12 with AuNPs in accordance with the strategy previously described 
(AuNP-12, Figure 5A, Figure S16 and Table S5).44 In this occasion, the synthetic effort 
was greatly reduced by omitting the extension of the glycopeptide with a CD4 T-cell 
peptide epitope and the immunogenic formulation was administered to the mice without 
any additional adjuvant.  
The success of the conjugation reactions was easily confirmed through gel 
electrophoresis analysis, in which the conjugated AuNP-12 is characterized by a 
reduced electrophoretic mobility relative to the precursor, linker-functionalized AuNPs 
(Figure 5B). Additionally, a significant increase in hydrodynamic diameter was observed 
with dynamic light scattering (DLS, Table S5) upon conjugation. Peptide loading was 
determined by amino acid analysis to be 200 glycopeptides/AuNP. 
Next, a standard immunization strategy was followed to test in vivo the immunogenic 
potential of AuNP-12. Thus, a group of five balb/c mice were immunized with a prime 
dose followed by three equal booster doses of AuNP-12 (each dose corresponds to 2 
µg of the glycopeptide) at 21-days intervals whereas a control group was treated with 
phosphate buffered saline (PBS) as shown in Figure 5B. A week after the last booster 
dose, the mice were sacrificed, and the serum harvested. Analysis of the antisera 
showed that AuNP-12 can elicit a significant anti-MUC1 IgG antibody response. The 
total antibody endpoint titers (Figure S18) were better than those observed for the 
previously reported AuNP-based vaccine candidate in the presence of complete 
Freund's adjuvant.44 This result demonstrates that this adjuvant is fully dispensable for 
administration of our AuNP-based vaccine candidate, which are therefore self-adjuvating 
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in their own right. Non-negligible IgM titers were also observed (although these were 
significantly lower than IgG titers), which suggests that glycopeptide 12 on AuNPs can 
induce class-switch recombination even without the use of a “universal” CD4 T-cell 
peptide. Next, the antibody isotypes in the antisera were evaluated. IgG1 was the 
predominant antibody in all antisera (Figure 5C), which suggests that Th2 type immune 
responses were predominantly induced by AuNP-12 in these mice. Finally, IgG2a, IgG2b 
and carbohydrate-related IgG3 antibodies45 were detected in all animals albeit weakly.
Figure 5. (A) Schematic representation of the vaccine candidate containing the 
engineered MUC1-like glycopeptide 12 attached to the surface of gold nanoparticles 
(AuNP-12). (B) Agarose gel electrophoresis of AuNP-linker (loaded with the SM(PEG)2-
linker. See Supporting Information) and AuNP-12. (C) Total and sub-typing (IgG1, 
IgG2a/b, IgG3 and IgM) anti-MUC1 antibodies after immunizing mice (n=5) with AuNP-
12. The ELISA plates were coated with glycopeptide 12 conjugated to bovine serum 
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albumin. Horizontal lines indicate the mean for the group of 5 mice. Asterisks indicate 
statistically significant difference (*** P < 0.005, ** P < 0.01, * P < 0.05) and NS indicates 
no significant difference.
To confirm that the elicited antibodies were able to recognize selectively the native 
tumor-associated MUC1 antigen on human cancer cells, two human cancer cell lines 
(MCF-7, T47D) and the human embryonic kidney cell line (HEK293T) were stained with 
the mice antisera and analyzed by flow cytometry (Figure 6A). Indeed, the antisera 
reacted strongly with MCF-7 and T47D cells, which express tumor-associated MUC1 on 
their surface. Conversely, negligible low binding was observed for HEK293T cells, which 
is consistent with the lack of MUC1 on their surface. These results are in good agreement 
with those obtained from confocal microscopy (Figure 6B) that show the presence of the 
MUC1 antigen on the surface of MCF-7 and T47D cells (green color), but not on 
HEK293T cells. Notably, the antisera also positively stained cancer cells from biopsies 
of breast-cancer patients (right panel in Figure 6C and Figure S19), but no staining is 
observed in case of cells from healthy patients. Thus, these results demonstrate the 
antigen mimic potential of unnatural glycopeptide 12.
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Figure 6. (A) Staining of living cells with the antisera of mice immunized with AuNP-12 
analyzed by flow cytometry: HEK293T (black line), MCF7 (orange line) and T47D (red 
line). Staining with 1:100 dilution of sera and visualization with a mouse secondary α-
IgG-488 antibody. (B) Confocal microscopy images show that mice antisera after 
vaccination with AuNP-12 do not stain HEK293T cells as expected because these cells 
do not express tumor-associated MUC1 on their surface. On the contrary, breast cancer 
cells MCF7 and T47D expressing tumor-associated MUC1 are positively stained by mice 
antisera. Blue = Hoechst (nuclei); Green = secondary anti-mouse IgG Alexa 488 (tumor-
associated MUC1); Red = CellMask Deep Red (membrane dye). (C) The antisera of 
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mice vaccinated with AuNP-12, positively stain tissue biopsies from breast-cancer 
patients. Blue = Hoechst (nuclei); Green = secondary anti-mouse IgG Alexa 488 (tumor-
associated MUC1).
Conclusions 
Our experimental evidence strongly suggests that it is possible to fine-tune the 
conformational preferences of GalNAc-containing glycopeptides in solution by 
employing a simple oxygen-for-sulfur or oxygen-for-selenium substitution at the 
glycosidic linkage. These simple chemical modifications have a significant structural 
impact allowing the peptide backbone to adopt a preorganized structure that is optimally 
suited for antibody binding, as confirmed by the improved binding affinity to a model anti-
MUC1 antibody. Additionally, the potential of a dually modified glycopeptide (fPro and 
SThr) as tumor-associated MUC1 antigen mimic has been demonstrated in vivo. 
Significantly, the antisera of mice vaccinated with AuNP-12 recognize cancer cells with 
high selectivity in biopsies of breast-cancer patients. This result confirms that the 
antibodies generated against the engineered antigen are able to recognize the naturally 
occurring antigen in its physiological context. Finally, we envision the strategy presented 
here to be of general interest because it may be applied to modulate the affinity of 
biologically relevant glycopeptides towards their receptors.
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